| Mr Keith Gist, CRNA | |
|
4519 N Garfield St Ste 15, Midland, TX 79705-3400 | |
| (432) 699-0225 | |
| Not Available |
| Full Name | Mr Keith Gist |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 4519 N Garfield St Ste 15, Midland, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043637838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 758719 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Martin County Hospital District | Stanton, TX | Hospital |
| Mitchell County Hospital District | Colorado city, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Global Anesthesia Services Pllc | 6608292818 | 2 |
| Martin County Hospital District | 8527958552 | 13 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | County Of Ward |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881782423 PECOS PAC ID: 1456261494 Enrollment ID: O20040414001322 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | Mitchell County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184631673 PECOS PAC ID: 9739071176 Enrollment ID: O20040614001226 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | Martin County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679560866 PECOS PAC ID: 8527958552 Enrollment ID: O20040805001106 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | County Of Ward |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1720096019 PECOS PAC ID: 1456261494 Enrollment ID: O20061104000162 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | Clinical Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518265966 PECOS PAC ID: 8325217904 Enrollment ID: O20110816000816 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | Texas Anesthesia Partners, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144673468 PECOS PAC ID: 3870879828 Enrollment ID: O20170406000406 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Entity Name | Global Anesthesia Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922618560 PECOS PAC ID: 6608292818 Enrollment ID: O20200819000627 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Keith Gist, CRNA Po Box 4157, Midland, TX 79704-4157 Ph: (432) 699-0225 | Mr Keith Gist, CRNA 4519 N Garfield St Ste 15, Midland, TX 79705-3400 Ph: (432) 699-0225 |
News Archive
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation.
A selection of opinions and editorials on the controversy surrounding the administration's regulation mandating insurance coverage for women of birth control.
A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.
› Verified 5 days ago
Zachary Belew, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4519 N Garfield St, Suite 15, Midland, TX 79705 Phone: 432-699-0225 | |
Warren D Bartley, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2706 W Cuthbert, Bldg B Ste 100, Midland, TX 79704 Phone: 432-699-0952 Fax: 432-520-2181 | |
Ronald W Henderson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2706 W Cuthbert, Bldg B Ste 100, Midland, TX 79704 Phone: 432-699-0952 Fax: 432-520-2181 | |
Christi Robinson, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2106 N Midland Dr, Midland, TX 79707 Phone: 817-908-1551 | |
Billy E Haggerty Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2706 W Cuthbert, Bldg B Ste 100, Midland, TX 79704 Phone: 432-699-0952 Fax: 432-520-2181 | |
Warren R Dill, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2706 W Cuthbert Ave, Building B, Ste 100, Midland, TX 79701 Phone: 432-699-0306 Fax: 432-520-2181 |